![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
IT Riluzole (riluzole)is a intrathecally delivered glutamate antagonist. It is being evaluated for the treatment of amyotrophic lateral sclerosis & other central nervous system diseases.
Lead Product(s): Riluzole
Therapeutic Area: Neurology Product Name: IT-Riluzole
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2024